Dudás István, Gidai János, Czeizel Andrew E
Foundation for the Community Control of Hereditary Diseases, 1026 Törökvész lejtõ 32, Budapest, Hungary.
Congenit Anom (Kyoto). 2006 Dec;46(4):194-8. doi: 10.1111/j.1741-4520.2006.00128.x.
Hydroxyprogesterone, a synthetic progestin, was used for the treatment of pregnant women with threatened abortion and preterm delivery. Previous studies showed some association between hydroxyprogesterone use during early pregnancy and some specific congenital abnormalities. The population-based large Hungarian data set seemed to be appropriate to check this possible association. The Hungarian Case-Control Surveillance of Congenital Abnormalities between 1980 and 1996 includes 22 843 cases with congenital abnormalities and 38 151 controls without any defect. 318 (1.4%) cases, while 433 (1.1%) controls had mothers with hydroxyprogesterone treatment during pregnancy (adjusted POR with 95% CI: 1.3, 1.1-1.5). However, there was no association between risk for any congenital abnormality group and a higher use of maternal hydroxyprogesterone treatment during the second and third month of gestation. On the other hand hydroxyprogesterone is not effective in the prevention of preterm delivery. In conclusion, there was no detectable risk for congenital abnormalities in the offspring of mothers with hydroxyprogesterone treatment during early pregnancy, however, there is no reasonable indication of this treatment during pregnancy.
羟孕酮，一种合成孕激素，曾用于治疗有先兆流产和早产风险的孕妇。先前的研究表明，孕早期使用羟孕酮与某些特定的先天性异常之间存在一定关联。基于人群的大型匈牙利数据集似乎适合检验这种可能的关联。1980年至1996年匈牙利先天性异常病例对照监测研究纳入了22843例先天性异常病例和38151例无任何缺陷的对照。318例（1.4%）病例和433例（1.1%）对照的母亲在孕期接受了羟孕酮治疗（校正比值比及95%置信区间：1.3，1.1 - 1.5）。然而，在妊娠第二和第三个月期间，任何先天性异常组的风险与母亲更高剂量使用羟孕酮治疗之间并无关联。另一方面，羟孕酮在预防早产方面无效。总之，孕早期接受羟孕酮治疗的母亲所生后代中未发现可检测到的先天性异常风险，然而，孕期进行这种治疗并无合理依据。
